Eyepoint Pharmaceuticals (EYPT) Projected to Release Quarterly Earnings on Wednesday

Eyepoint Pharmaceuticals (NASDAQ:EYPT) is anticipated to announce its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.9304) per share and revenue of $0.23 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Wednesday, August 5th. The company reported ($1.09) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.08). The firm had revenue of $0.51 million for the quarter, compared to the consensus estimate of $0.45 million. On average, analysts expect Eyepoint Pharmaceuticals to post ($3.46) EPS for the current fiscal year and ($2.01) EPS for the next fiscal year.

Eyepoint Pharmaceuticals Trading Down 0.7%

NASDAQ EYPT opened at $0.36 on Wednesday. Eyepoint Pharmaceuticals has a 1-year low of $0.36 and a 1-year high of $19.11. The company has a 50 day moving average of $3.53 and a 200-day moving average of $11.25. The company has a market cap of $31.31 million, a price-to-earnings ratio of -0.10 and a beta of 1.67.

Wall Street Analyst Weigh In

Several brokerages have weighed in on EYPT. Mizuho reaffirmed a “neutral” rating and issued a $0.50 price objective on shares of Eyepoint Pharmaceuticals in a report on Tuesday, October 20th. Weiss Ratings upgraded Eyepoint Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 1st. HC Wainwright reaffirmed a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, October 20th. Royal Bank Of Canada cut their price objective on shares of Eyepoint Pharmaceuticals to $1.00 and set a “sector perform” rating for the company in a research report on Tuesday, October 20th. Finally, Guggenheim cut shares of Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Monday, October 19th. Two investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $21.85.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for serious eye diseases. The company specializes in sustained-release drug delivery for the retina and other parts of the eye, with the goal of reducing the frequency of injections and improving treatment convenience for patients.

EyePoint’s commercial products include YUTIQ, an injectable fluocinolone acetonide intravitreal implant used to treat chronic noninfectious posterior uveitis, and DEXYCU, an ophthalmic formulation of dexamethasone used to treat inflammation following ocular surgery.